文献速递男科与性医学

辛伐他汀与Rho激酶抑制剂Y-27632通过抑制YAP/TAZ核转位阻止佩罗尼病成纤维细胞向肌成纤维细胞转化

Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.
PubMed 文献 · BJU Int · 2019-01-06

该体外研究从佩罗尼病(PD)患者手术获取的白膜组织分离原代人成纤维细胞,用3 ng/mL TGF-β1诱导肌成纤维细胞转化,并加入递增剂量的Y-27632或辛伐他汀。结果显示两种药物均能抑制α-SMA、III型胶原、弹性蛋白和CTGF的mRNA表达,逆转α-SMA蛋白升高,且不损害细胞活力,机制涉及阻止YAP/TAZ核转位。作者认为Y-27632和辛伐他汀可能成为PD早期治疗的新选择。

要点

  • TGF-β1刺激72小时使α-SMA表达上调6至10倍,成功诱导肌成纤维细胞转化。
  • Y-27632或辛伐他汀在RNA和蛋白水平抑制TGF-β1诱导的纤维化标志物表达。
  • 两种药物通过抑制YAP/TAZ核转位发挥作用,且不影响细胞活力。

核心结论

  • Rho激酶抑制和辛伐他汀治疗可在RNA和蛋白水平阻止TGF-β1刺激的成纤维细胞向肌成纤维细胞转化,机制为抑制YAP/TAZ核转位。
  • Y-27632和辛伐他汀可能成为佩罗尼病早期治疗的新选择。

研究设计与样本

  • 体外研究:从佩罗尼病患者手术获取的阴茎白膜组织分离原代人成纤维细胞。
  • 用3 ng/mL TGF-β1刺激诱导肌成纤维细胞状态,并加入递增剂量的Y-27632和辛伐他汀。
  • 采用实时定量PCR、Western blot、免疫荧光和基于刃天青的细胞活力检测进行评估。

主要发现

  • TGF-β1刺激72小时后,α-SMA表达上调6至10倍。
  • Y-27632或辛伐他汀处理可抑制α-SMA、III型胶原、弹性蛋白和CTGF的mRNA表达。
  • TGF-β1刺激使α-SMA蛋白表达增加2倍,经Y-27632和辛伐他汀处理后恢复至未刺激水平。
  • 免疫荧光显示刺激细胞为α-SMA+、Vim+的肌成纤维细胞,而未刺激及药物处理细胞为α-SMA-、Vim+。
  • 基于刃天青的检测证实给药未损害细胞活力。

临床怎么用

  • 提示辛伐他汀和Rho激酶抑制剂可能作为佩罗尼病早期抗纤维化治疗的候选药物。
  • 临床转化前需进一步开展体内和临床研究验证疗效与安全性。

局限性

  • 研究为体外细胞实验,结论不能直接推广至人体。
  • 原文未报告样本量、具体药物浓度范围及统计学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To uncover the anti-myofibroblast (MFB) properties of Rho-kinase inhibitor (compound Y-27632) and simvastatin in an in vitro model of Peyronie's disease (PD), a sexually debilitating disease caused by an irreversible fibrotic plaque in the penile tunica albuginea (TA). MATERIALS AND METHODS: Primary human fibroblasts (FBs) were isolated from surgically obtained TA tissue from patients with PD. To induce MFB status, cells were stimulated with 3 ng/mL transforming growth factor-β1 (TGF-β1). Increasing doses of Y-27632 and simvastatin were added. Real-time quantitative PCR was used to assess mRNA expression of α-smooth muscle actin (α-SMA), collagen III, elastin and connective tissue growth factor (CTGF) after 72 h. Western blot analysis was used to quantify α-SMA protein contents, and immunofluorescence (IF) was used to visualize MFB differentiation by staining for α-SMA after 72 h. A resazurin-based assay was used to assess cell viability to ensure the anti-MFB effect of the drugs. A mechanistic study was performed using IF staining for YAP/TAZ nuclear translocation. RESULTS: After 72 h of stimulation with TGF-β1, a six- to 10-fold upregulation of α-SMA could be observed. When treated with Y-27632 or simvastatin, the α-SMA, collagen III, elastin and CTGF mRNA expression was impeded. Additionally, TGF-β1 stimulation showed a twofold increase in α-SMA protein expression, which was reversed to non-stimulated levels after treatment with Y-27632 and simvastatin. Using IF, stimulated cells were identified as MFB (α-SMA+, Vim+) as opposed to the non-stimulated, Y-27632- and simvastatin-treated cells (α-SMA-, Vim+). The resazurin-based assay confirmed that the cell viability was not compromised by the administered drugs. On stimulation with TGF-β1, nuclear translocation of YAP/TAZ could be observed, which was prevented by adding the aforementioned compounds. CONCLUSION: Transformation of FBs into the contractile and extracellular matrix-producing MFBs occurs after TGF-β1 stimulation. In our experiments, Rho-kinase inhibition and simvastatin treatment were shown to prevent this in TGF-β1-stimulated cells on an RNA and protein level through the inhibition of YAP/TAZ nuclear translocation. Y-27632 and simvastatin could become a novel treatment option in the early treatment of PD.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Milenkovic U, Ilg MM, Zuccato C, et al. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. BJU Int. 2019. PMID: 30536599. doi:10.1111/bju.14638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。